4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

59 Suppliers, 23 USDMF, 14 CEP/COS, 7 JDMF, 15 EU WC, 25 KDMF, 19 NDC API, 36 Listed Suppliers

DEVELOPMENTS

44 Drug(s) in Development

44 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

13 Suppliers

13 Suppliers

DOSSIERs // Finished Dosage Forms

312 Dossiers, 62 FDA Orange Book, 63 Europe, 34 Canada, 32 Australia, 44 South Africa, 77 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 15MG, TABLET;ORAL - 7.5MG, SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

Suppliers, 27 Roquette, 26 Kerry, 20 BASF, 12 Microlex e.U, 11 Gangwal Healthcare, 11 Sigachi Industries, 11 DKSH, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 SPI Pharma, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Chemicals, 7 Actylis, 7 DFE Pharma, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 5 Pluviaendo, 5 Prachin Chemical, 5 Pharmatrans-Sanaq, 4 Vasa Pharmachem, 4 Ingredion Pharma Solutions, 4 ACG Worldwide, 3 Lonza Capsugel, 3 Nanjing Well Pharmaceutical, 3 Ulanqab Kema New Material, 3 Rochem International Inc, 2 Alcedo Pharmachem, 2 Ideal Cures Pvt Ltd, 2 Jai Radhe Sales, 2 Zhejiang Huakang Pharmaceutical, 2 Novo Excipients, 1 Minakem, 1 Evonik, 1 Nanjing Bold Chemical, 1 Qualicaps, 1 Seppic, 1 Shijiazhuang Huaxu Pharmaceutical, 1 NEWEDGE Overseas, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Chynops Pharma

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders, 43 Disintegrants & Superdisintegrants, 36 Direct Compression, 25 Granulation, 24 Thickeners and Stabilizers, 20 Lubricants & Glidants, 17 Coating Systems & Additives, 16 Taste Masking, 15 Co-Processed Excipients, 14 Chewable & Orodispersible Aids, 13 Controlled & Modified Release, 11 Film Formers & Plasticizers, 11 Solubilizers, 9 Parenteral, 8 Empty Capsules, 7 Topical, 5 Rheology Modifiers, 3 API Stability Enhancers, 3 Emulsifying Agents, 2 Coloring Agents, 1 Soft Gelatin

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 51 Finished Drug Prices

MARKET PLACE

32 APIs, 2 DOSSIERS // FDF, 1 Intermediates

PATENTS

81 US Patents, 8 US Exclusivities, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 BioAnalytical Methods, 5 EDQM, 6 USP, 6 Others

DIGITAL CONTENT

3 Data Compilation & Company Tracker #PharmaFlow, 44 News

Information, Expiry & Status of Health Canada Patents covering 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide.

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

59 Suppliers

23 USDMF

14 CEP/COS

7 JDMF

15 EU WC

25 KDMF

19 NDC API

36 Listed Suppliers

DEVELOPMENTS

44 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

13 Suppliers

DOSSIERs // Finished Dosage Forms

312 Dossiers

62 FDA Orange Book

63 Europe

34 Canada

32 Australia

44 South Africa

77 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 15MG

TABLET;ORAL - 7.5MG

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

Suppliers

27 Roquette

26 Kerry

20 BASF

12 Microlex e.U

11 Gangwal Healthcare

11 Sigachi Industries

11 DKSH

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 SPI Pharma

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Chemicals

7 Actylis

7 DFE Pharma

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

5 Pluviaendo

5 Prachin Chemical

5 Pharmatrans-Sanaq

4 Vasa Pharmachem

4 Ingredion Pharma Solutions

4 ACG Worldwide

3 Lonza Capsugel

3 Nanjing Well Pharmaceutical

3 Ulanqab Kema New Material

3 Rochem International Inc

2 Alcedo Pharmachem

2 Ideal Cures Pvt Ltd

2 Jai Radhe Sales

2 Zhejiang Huakang Pharmaceutical

2 Novo Excipients

1 Minakem

1 Evonik

1 Nanjing Bold Chemical

1 Qualicaps

1 Seppic

1 Shijiazhuang Huaxu Pharmaceutical

1 NEWEDGE Overseas

1 Shanghai Welltone Material Technology Co., Ltd

1 Chynops Pharma

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons